Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the first gene therapy administered as a treatment in a real-world setting for hemophilia B in Europe. HEMGENIX® is the first one-time gene therapy approved in Europe for the treatment of adults with severe and moderately severe hemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.¹ Source: BERNAMA News Agency
CSL BEHRING ANNOUNCES FIRST TWO PATIENTS TREATED WITH HEMGENIX® (ETRANACOGENE DEZAPARVOVEC) GENE THERAPY FOR HEMOPHILIA B IN EUROPE
Search
Recent Posts
ILO Governing Body Adopts Enhanced Development Programme for Palestine
November 13, 2026
West Bank and Gaza Face Mobility Challenges Amid Israeli Occupation
November 13, 2026
Arab Parliament Condemns Israeli Attack on Gaza Medical Complex
November 13, 2026
Gulf Cooperation Council Denounces Israeli Actions in Gaza
November 13, 2026
Palestinian Casualties Reported in Israeli Military Operations in Gaza
November 13, 2026
- - General
CSL BEHRING ANNOUNCES FIRST TWO PATIENTS TREATED WITH HEMGENIX® (ETRANACOGENE DEZAPARVOVEC) GENE THERAPY FOR HEMOPHILIA B IN EUROPE
ILO Governing Body Adopts Enhanced Development Programme for Palestine
November 13, 2026
West Bank and Gaza Face Mobility Challenges Amid Israeli Occupation
November 13, 2026
Advertisement